InLighta Biosciences

Inlighta® Biosciences LLC was established in May 2012 with the objective of developing MRI contrast agents for diagnostic imaging. InLighta has designed a novel class of Gd-based blood pool and biomarker-targeted protein contrast agents (ProCAs) with significantly increased r1 and r2 relaxivity values. InLighta’s core product, collagen targeting contrast agent ProCA32.collagen, has demonstrated superior performance compared with commercially available contrast agents, delivering a 100% increase in accuracy following a single injection for both T1-weighted and T2-weighted imaging, particularly for heart and lung fibrosis, cardiovascular diseases and tumors in liver tissues. InLighta can enter three distinct markets for diagnostic imaging: medical diagnostic imaging of the heart, lung, and liver; molecular imaging of biomarkers for non-invasive detection and classification of disease types for treatment (directly competing with biopsy); and development of companion diagnostics to accelerate the development of therapeutic drugs to treat cancers, metastasis, and fibrosis. 

This technology, which is expected to be eligible for FDA Fast Track and/or Breakthrough designations, is protected by a robust patent portfolio licensed exclusively to InLighta through Georgia State University.